Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia

Volc, Sáhlua Miguel; Almeida, Maria T. A.; Abadi, Márcia Datz; Cornacchioni, Ana Lucia; Filho, Vicente Odone; Cristófani, Lílian Maria

doi:10.2223/jped.1531

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aytaç et al found this rate 55% after HSCT [17]. These rates were 65% and 70% in other studies [18,19]. Our immunosuppressive patient was diagnosed with ALL and treated with cyclosporine and mycophenolate mofetil for the diagnosis of GVHD.…”

Section: Discussionsupporting

confidence: 59%

Measles, One of the Re-emerging Diseases

Türe¹

2016

Journal of Microbiology and Infectious Diseases

View full text Add to dashboard Cite

Objective:The aim of the study is to stand out the measles which is a highly contagious re-emerging viral illness and may cause severe complications in susceptible population. Methods:This retrospective study was conducted on patients who were diagnosed with measles in the department of Infectious Diseases, Erciyes University Hospital, between January 2013 and February 2014. The diagnosis of measles was confirmed by measles specific immunoglobulin M (IgM) antibody positivity in serum samples. Results:Nine patients were included the study. Three patients had a co-morbid condition including hematopoietic stem cell transplantation, pregnancy and diabetes mellitus. Four of the patients had hepatitis and one of them had pneumonia as a complication. Conclusion: Susceptible population, especially immunocompromised people are still at risk about measles. Adherence to universal vaccination programs is determinative in terms of breaking out of an outbreak. J Microbiol Infect Dis 2016;6(1): 19-22 ÖZET Amaç: Çalışmanın amacı bulaştırıcılığı yüksek ve ağır komplikasyonlarla seyreden viral bir enfeksiyon hastalığı olan kızamığa dikkat çekmektir. Yöntemler: Ocak 2013-Şubat 2014 tarihleri arasında Erciyes üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Bölümü'nde kızamık tanısı ile takip edilen hastalar retrospektif olarak incelendi. Kızamık tanısı serum örneğinde kızamık spesifik immunoglobulin M pozitifliği ile doğrulandı. Bulgular: Çalışmaya dokuz hasta alındı. Hematopoetik kök hücre nakli, gebelik ve diyabetes mellitus olmak üzere üç hastada komorbidite mevcuttu. Kızamık komplikasyonu olarak dört hastada hepatit, bir hastada pnömoni gelişti. Sonuç: Duyarlı popülasyon ve özellikle immunosupresif hastalar kızamık açısından risk altındadır. Salgınların önlenmesi için aşılama programlarına uyum önemlidir.

show abstract

Section: Discussionsupporting

confidence: 59%

Measles, One of the Re-emerging Diseases

Türe¹

2016

Journal of Microbiology and Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…9 However, other studies have also shown no effect of age on posttreatment vaccine titers in children with ALL. 16,17 While these studies and ours showed that some trends do exist, what is important is that considerable portions of individuals exhibit loss of immunogenicity against VPDs following chemotherapy in all ages throughout these studies.…”

Section: Discussionmentioning

confidence: 60%

Post-Chemotherapy Titer Status and Need for Revaccination After Treatment for Childhood Cancer

Zhang

Thornton

Ruble

et al. 2020

Clin Pediatr (Phila)

View full text Add to dashboard Cite

Objectives. To evaluate the strategy of checking vaccine titers after completion of chemotherapy. Study Design. Retrospective review of pediatric oncology patients who completed chemotherapy. Demographics, post-chemotherapy titers, and absolute lymphocyte counts (ALCs) were analyzed. Results. Ninety patients met inclusion criteria, and 87% of patients had at least one titer checked. Comparing patients <7 years and those ≥7 years at diagnosis, there was no difference in incidence of negative titers except mumps; those <7 years old were more likely to have negative titers (58% vs 20%, P = .003). Comparing those <13 years old to ≥13 years old, there was no difference in negative titers except mumps (45% vs 19%, P = .02) and tetanus (44% vs 0%, P = .002). No patient maintained all protective titers after completion of chemotherapy. Time to ALC recovery was not predictive of positive titers. Conclusion. Checking titers after chemotherapy is not recommended. Providers should assume loss of immunity.

show abstract

“…For example, it is known that children undergoing therapy for acute lymphoblastic leukemia (ALL) have low measles antibody levels following chemotherapy despite prior vaccination; limited humoral responses may be most profound in children under 5 years of age [19][20][21]. Protective levels of measles antibody range between 13% and 70% in children with ALL and appear to depend on the age of the child and the chemotherapeutic regimen [22][23][24][25]. Data on adults with leukemia are even less well described but may be somewhat better than in children [26].…”

Section: Introductionmentioning

confidence: 99%

Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy

Pergam

Englund

Kamboj

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Until recently, measles exposures were relatively rare and so, consequently, were an afterthought for cancer patients and/or blood and marrow transplant recipients and their providers. Declines in measles herd immunity have reached critical levels in many communities throughout the United States due to increasing vaccine hesitancy, so that community-based outbreaks have occurred. The reemergence of measles as a clinical disease has raised serious concerns among immunocompromised patients and those who work within the cancer and hematopoietic cell transplantation (HCT) community. Since live attenuated vaccines, such as measles, mumps, and rubella (MMR), are contraindicated in immunocompromised patients, and with no approved antiviral therapies for measles, community exposures in these patients can lead to life-threatening infection. The lack of data regarding measles prevention in this population poses a number of clinical dilemmas. Herein specialists in Infectious Diseases and HCT/cellular therapy endorsed by the American Society of Transplant and Cellular Therapy address frequently asked questions about measles in these high-risk cancer patients and HCT recipients and provide expert opinions based on the limited available data.

show abstract

Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia

Cited by 3 publications

References 0 publications

Measles, One of the Re-emerging Diseases

Measles, One of the Re-emerging Diseases

Post-Chemotherapy Titer Status and Need for Revaccination After Treatment for Childhood Cancer

Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy

Contact Info

Product

Resources

About